Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 9/20 | 0.49 |
| ▸ | TACR1 | P25103 | 7/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL366662 | 1.00 | SCN4A (0.49) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL22502109 | 1.00 | SCN4A (0.49) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL6504637 | 0.85 | SCN4A (0.40) | SCN4ATACR1 | |
| SCHEMBL1516258 | 0.85 | DPP4 (0.37) | SCN4ATACR1 | |
| SCHEMBL12487435 | 0.85 | SCN4A (0.40) | SCN4ATACR1 | |
| SCHEMBL6504640 | 0.85 | SCN4A (0.40) | SCN4ATACR1 | |
| SCHEMBL23215033 | 0.83 | IDO1 (0.35) | SCN4ATACR1 | |
| SCHEMBL16761917 | 0.83 | SCN4A (0.32) | SCN4ATACR1 | |
| SCHEMBL16793913 | 0.83 | DPP4 (0.35) | SCN4ATACR1 | |
| SCHEMBL6124751 | 0.83 | IDO1 (0.35) | SCN4ATACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076606-A | Imidazopyridazine IL-17 inhibitor compounds | 詹森药业有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-111527084-B | Isofuranone compounds useful as HPK1 inhibitors | 百时美施贵宝公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-3707138-B1 | ISOFURANONE COMPOUNDS USEFUL AS HPK1 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-07-13 | — | — | EP | disclosed |
| US-11166959-B2 | Isofuranone compounds useful as HPK1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200390776-A1 | ISOFURANONE COMPOUNDS USEFUL AS HPK1 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-12-17 | — | — | US | disclosed |
| CN-111527084-A | Isofuranone compounds useful as HPK1 inhibitors | 百时美施贵宝公司 | 2020-08-11 | — | — | CN | disclosed |
| EP-2323659-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010017150-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390776-A1 | ISOFURANONE COMPOUNDS USEFUL AS HPK1 INHIBITORS | IP6K1, SIK1, HIPK1 | SCN4A 3374/4885TACR1 4501/4885CACNA1F 3104/4885 |
| US-20100035919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | ROCK1, ROCK2, RHOA | SCN4A 3298/4885TACR1 2756/4885CACNA1F 3506/4885 |
| US-11166959-B2 | Isofuranone compounds useful as HPK1 inhibitors | IP6K1, SIK1, HIPK1 | SCN4A 3374/4885TACR1 4501/4885CACNA1F 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.